Trial Profile
An Open-Label Phase 2 Study of Maintenance Therapy With OST31-164 After Resection of Recurrent Osteosarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs ADXS 31164 (Primary)
- Indications Osteosarcoma
- Focus Registrational; Therapeutic Use
- Acronyms OST-164-01
- Sponsors OS Therapies
- 26 Sep 2023 Status changed from active, no longer recruiting to completed.
- 26 Sep 2023 According to an OS Therapies media release, the trial is being conducted at 21 Children's Oncology Group (COG) sites across the country.
- 26 Sep 2023 Status changed from recruiting to active, no longer recruiting according to OS Therapies media release.